ADMA BIOLOGICS, INC.: Rubric Capital Management LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Rubric Capital Management LP disclosed a stake exceeding 5% in ADMA Biologics, Inc. via a Schedule 13G filing with the SEC (accession 0001104659-26-128292). The exact share count and percentage were not specified in the filing headline. The disclosure signals a significant new institutional position in the commercial biopharmaceutical company, which specializes in plasma-derived biologics and immune globulin products. Investors will watch for further detail on Rubric's position size and any subsequent 13D-style activism, as well as ADMA's next quarterly results for signs of institutional conviction.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Rubric Capital Management LP, ADMA Biologics, Inc.